PLoS ONE · 2018 · 63 citations · 27 references
MedicineRadiation OncologyRadiologyBiomedical ImagingDiagnostic ImagingDiagnostic RadiologyAdaptive RadiotherapyComputed TomographyMedical ImagingRadiation TherapyTumor CharacterizationTumor ImagingConcurrent Chemoradiation TherapyImage-based Diagnostic FeaturesNon-small Cell Lung Cancer ImagingNon-small Cell Lung Cancer TreatmentRadiomic AnalysisRadiomic Feature ExtractionRadiomicsRadiomics In Lung Cancer
The primary goal of precision medicine is to minimize side effects and optimize efficacy of treatments. Recent advances in medical imaging technology allow the use of more advanced image analysis methods beyond simple measurements of tumor size or radiotracer uptake metrics. The extraction of quantitative features from medical images to characterize tumor pathology or heterogeneity is an interesting process to investigate, in order to provide information that may be useful to guide the therapies and predict survival. This paper discusses the rationale supporting the concept of radiomics and the feasibility of its application to Non-Small Cell Lung Cancer in the field of radiation oncology research. We studied 91 stage III patients treated with concurrent chemoradiation and adaptive approach in case of tumor reduction during treatment. We considered 12 statistics features and 230 textural features extracted from the CT images. In our study, we used an ensemble learning method to classify patients' data into either the adaptive or non-adaptive group during chemoradiation on the basis of the starting CT simulation. Our data supports the hypothesis that a specific signature can be identified (AUC 0.82). In our experience, a radiomic signature mixing semantic and image-based features has shown promising results for personalized adaptive radiotherapy in non-small cell lung cancer.
27
A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection
Ron Kohavi · 1995 · 10.7K citations · Full text
A New Initiative on Precision Medicine
Francis S. Collins, Harold Varmus · New England Journal of Medicine · 2015 · 5.2K citations · Full text
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text